Absstract of: AU2025242780A1
Disclosed herein are therapeutic methods and compositions for the treatment of atherosclerosis and regression of a distal atherosclerotic plaque, wherein the composition is administered to a subject and targeted to the liver.
Absstract of: WO2026232080A1
The present disclosure includes methods for preventing, treating, and monitoring cardiovascular disease based on the gut mycobiome and host genetics. Methods include: collecting a microbiome sample for a subject; analyzing the sample for a presence and abundance of a species belonging to the genus or species Kazachstania causally linked to cardiovascular disease risk by Mendelian Randomization analysis; and/or when the presence of the species belonging to Kazachstania is below a clinically relevant threshold, administering to the subject a composition including a fungal culture of Kazachstania and/or one or more cardiovascular disease medications to prevent an occurrence of or prevent further progression of the cardiovascular disease. Methods also include collecting a genetic sample from a subject and detecting the presence of cardiovascular risk-associated alleles associated with the abundance of Kazachstania. Compositions for preventing or treating a cardiovascular disease are also disclosed.
Absstract of: US20260337608A1
The present disclosure relates to compositions and methods of treating, preventing, or diagnosing cardiac fibrosis and related diseases by modulating alternative polyadenylation.
Absstract of: US20260335399A1
Heart failure WITH Preserved Ejection Fraction (HFpEF) effects approximately three million people in the United States.
Absstract of: US20260337660A1
Method of prediction of gestational diabetes mellitus including both its milder and more severe form. Pregnant women are screened to determine the expression profile of two or more miRNAs in whole peripheral venous blood collected in the period of 10th-13th gestational week, whereas said two or more miRNAs are selected from the group miR-1-3p, miR-20a-5p, miR-20b-5p, miR-23a-3p, miR-100-5p, miR-125b-5p, miR-126-3p, miR-181a-5p, miR-195-5p, miR-499a-5p, and miR-574-3p.
Absstract of: US20260337681A1
The present disclosure provides methods and kits for evaluating and risk stratifying subjects with HFpEF. Specifically, the present disclosure provides methods and kits for determining an expression profile of small, non-coding RNA biomarkers that can predict coronary flow reserve (CFR). CFR is an important clinical measure that is correlated to the presence of coronary microvascular dysfunction (CMD) and predicts morbidity in patients diagnosed with HFpEF. In other aspects, the present disclosure provides therapeutic compositions based on the small, non-coding RNA markers, for example, with the potential to correct dysregulation of several messenger RNA targets with an sRNA mimetic, or with the potential to inhibit expression or activity of the small RNA itself with an antisense oligonucleotide. The therapeutic compositions find use in subjects with CMD and/or HFpEF.
Absstract of: EP4831302A1
0001 Provided herein are compositions, methods, and kits for detecting Severe fever with thrombocytopenia syndrome virus (SFTSV) in human subjects. In certain embodiments, provided herein are SFTSV specific nucleic acid probes and primers, and methods for detecting SFTSV nucleic acid in human subjects.
Absstract of: US20260327704A1
This invention provides gene expression profiles useful for diagnosing atrial fibrillation in ischemic stroke and for distinguishing atrial fibrillation in ischemic stroke from arterial (large vessel) stroke or embolic stroke of undetermined source (ESUS).
Absstract of: WO2025125328A1
The invention provides therapeutic agents which can be used in the treatment of neuropathy, myopathy or cardio(myo)pathy. More particularly, the invention provides compounds which are capable of stimulating autophagy, methods for identifying subjects susceptible to treatment with such compounds and methods for identifying such compounds.
Absstract of: WO2026213966A1
The present invention relates to a use of PXDC1 in the preparation of a product for treating cardiac hypertrophy. The efficacy of inhibiting PXDC1 expression in treating cardiac hypertrophy and controlling the occurrence and progression of the cardiac hypertrophy has been demonstrated. Provided are a novel drug target and strategy for the treatment of cardiac hypertrophy, which can reduce the expression of cardiac hypertrophy biomarkers, decrease cardiomyocyte size, improve the ejection fraction and fractional shortening of the heart, lower the heart weight-to-body weight ratio, and mitigate the degree of cardiac fibrosis. In addition, the mechanism of action of PXDC1 in cardiac hypertrophy has been elucidated, deepening the understanding of the pathogenesis of the disease, and laying an important foundation for further exploration of cell biological and molecular biological processes related to cardiac hypertrophy.
Absstract of: CN122855651A
The invention belongs to the technical field of biomedicine, and particularly relates to a cardiovascular disease methylation marker and application thereof. The invention discloses a cardiovascular disease methylation marker for the first time. The cardiovascular disease methylation marker comprises a coronary artery endothelial cell methylation marker, a coronary artery smooth muscle cell methylation marker, a myocardial cell methylation marker and/or a heart fiber cell methylation marker. The method can be used for diagnosis, screening or risk stratification of cardiovascular diseases.
Absstract of: WO2026199076A1
Microvascular dysfunction has a wide array of clinical presentations, ranging from ischemic heart disease to renal failure, stroke, blindness, pulmonary arterial hypertension, and dementia. Unfortunately, the lack of clinically reliable biomarkers of microvascular injury or dysfunction is a major roadblock for assessing and preventing microvascular rarefaction in patients. Also, currently, there are no medications that can effectively treat and prevent microvascular diseases. The present application discloses methods for treating a microvascular disease and/or dysfunction in a subject based on the administration of miR-423-5p, let-7b-5p, let- 7a-5p, miR-30a-3p and/or let-7c-5p miRNA or RNA interfering agent mimicking one or more of these miRNAs. The present application discloses methods for assessing the risk of suffering from a microvascular disease or dysfunction by measuring the levels of at least one of miR-423-5p, let-7b-5p, let-7a-5p, miR-30a-3p and/or let-7c-5p miRNA in a sample.
Absstract of: CN122833163A
The invention belongs to the technical field of disease diagnostic reagents, and relates to application of a reagent for detecting a marker THBS1 in preparation of a diagnostic reagent for type 2 cardiac and renal syndromes. Aiming at the problems of difficult diagnosis and insufficient risk assessment of the type 2 cardiac and renal syndrome in the prior art, a new biomarker THBS1 is found, and the correlation between the marker and the attack of the type 2 cardiac and renal syndrome is confirmed; therefore, a reagent for detecting the marker THBS1 can be used for preparing related reagents for diagnosing the type 2 cardiac and renal syndrome and/or evaluating prognosis of the type 2 cardiac and renal syndrome. An animal model finds that the THBS1 level in mouse plasma of a type 2 heart and kidney syndrome model is remarkably increased, and the THBS1 can be used as a biomarker for diagnosing the type 2 heart and kidney syndrome disease. Therefore, the detection of the THBS1 level in the plasma can be used for assisting the diagnosis of the type 2 cardiac and renal syndrome or the evaluation of the prognosis of the type 2 cardiac and renal syndrome.
Absstract of: CN122833160A
The invention relates to the technical field of biological medicine, in particular to CD9-based PASC related cardiovascular system symptom risk assessment application. The invention provides a risk assessment system taking CD9 as a core molecular marker, and the system can provide objective and quantifiable molecular-level reference basis for risk assessment of PASC-related cardiovascular system symptoms under the condition that sufficient interpretation is difficult to provide by a conventional detection means.
Absstract of: CN122811359A
The invention belongs to the technical field of biomedicine, and particularly relates to a coronary heart disease methylation marker and application thereof. The invention discloses the coronary heart disease methylation marker for the first time, and the coronary heart disease methylation marker can be used for diagnosis, screening or risk stratification of coronary heart disease.
Absstract of: CN122811357A
The invention provides a primer probe composition and a kit for direct expansion detection of gene polymorphism of hypertension medication and an application method, and belongs to the technical field of molecular biology and in-vitro diagnosis. According to the present invention, the combination of the specific primer and the fluorescent probe is designed according to five hypertension clinical core medication gene loci such as ACE-rs1799752, AGTR1-rs5186, ADRB1-rs1801253, CYP2D6 * 10-rs1065852 and CYP2C9 * 3-rs1057910; whole blood direct expansion PCR and a fluorescent probe melting curve technology are combined, and five-site gene polymorphism detection is synchronously completed through a single reaction tube. According to the scheme, nucleic acid extraction and purification do not need to be carried out on a blood sample, closed tube operation is carried out in the whole process, aerosol cross contamination is effectively avoided, and the kit has the advantages of being easy and convenient to operate, rapid in detection, low in cost and accurate in typing, can be matched with a conventional fluorescent quantitative PCR instrument and provides a reliable molecular diagnosis basis for clinical hypertension precise medication.
Absstract of: CN122826463A
Compositions and methods are provided for evaluating patients suffering from suspected cerebral stroke in order to diagnostically differentiate acute ischemic cerebral stroke and subgroups thereof from intracerebral hemorrhage, transient cerebral ischemic attack, and cerebral stroke mimic disease; to predict responsiveness to treatment and adverse reactions after treatment; and predicting the possibility, life quality and survival rate of subsequent cerebral apoplexy.
Absstract of: US20260287596A1
Methods and compositions disclosed herein generally relate to methods of identifying, validating, and measuring clinically relevant, quantifiable biomarkers of diagnostic and therapeutic responses for blood, vascular, cardiac, and respiratory tract dysfunction, particularly as those responses relate to septic shock in pediatric patients. Certain aspects of the invention relate to identifying one or more biomarkers associated with septic shock in pediatric patients in combination with one or more endothelial-derived biomarkers, receiving a dataset comprising biomarker concentrations, wherein the dataset is from a sample obtained from a pediatric patient having at least one indication of septic shock, then determining whether the biomarker concentrations of each of the at least one biomarkers are greater than one or more pre-determined cut-off biomarker concentration, wherein the level of said biomarker correlates with a predicted outcome.
Absstract of: AU2026223366A1
% % $* $ + ($ + % $* $ ( $ + % $!, - % ./%0$ - 1!#,.02 % Abstract ug b s t r a c t u g
Absstract of: WO2026194092A1
Provided is a use of Gadd45g as a biomarker for cardiac hypertrophy. Provided is a use of a substance capable of reducing the activity and/or expression level of Gadd45g in peripheral blood and/or myocardial tissue. Further provided is a use of a substance targeting Gadd45g in the preparation of products. Provided is a use of mice having reduced Gadd45g activity and/or expression level in the preparation and/or screening of drugs. Provided is a kit for detecting Gadd45g.
Absstract of: CN122786494A
The invention discloses application of a GLUD1 inhibitor in preparation of a medicine for preventing and treating atherosclerosis. According to the application disclosed by the invention, the research finds that in an atherosclerosis model, the macrophage GLUD1 gene is remarkably up-regulated, which indicates that the GLUD1 gene can be used as a diagnosis marker of atherosclerosis, and the diagnosis of atherosclerosis can be quickly realized by detecting the expression level of the GLUD1 gene; the invention provides a new target for atherosclerosis treatment, opens up a new path and a new method, and brings inestimable benefits for delaying atherosclerosis and improving the living quality of patients.
Absstract of: CN122786495A
The invention discloses a pharmaceutical application of a substance for inhibiting NRDE2. The invention also discloses an application of a substance for knocking out the NRDE2 gene or inhibiting NRDE2 expression in preparation of a medicine for treating atherosclerosis. The NRDE2 is inhibited or knocked out, so that the plaque area can be reduced, the plaque stability can be improved, macrophage inflammation and aging can be inhibited, and the R-loop level can be reduced.
Absstract of: CN122772978A
The invention belongs to the technical field of molecular detection, and discloses a multi-site gene detection combination for coronary heart disease risk assessment and a detection method thereof, the detection combination comprises a PCR amplification primer pair and a corresponding single base extension primer, the PCR amplification primer pair is used for detecting 22 SNP sites of 16 coronary heart disease related genes, and the genes comprise PCSK9, APOE, APOB, MTHFR, LPL, LDLR, SLCO1B1, OLR1, ZPR1, CELSR2, ABCG8, SLC22A1, HFE, MYLIP, ST3GAL4 and NYNRIN. The detection method comprises the following steps: extracting genome DNA of a to-be-detected sample, carrying out multiple PCR amplification, single base extension and mass spectrometry detection, and carrying out coronary heart disease risk assessment according to a genotyping result. The method has the advantages of high detection flux, low cost, short period, good accuracy and suitability for clinical screening.
Absstract of: CN122772974A
The invention relates to the technical field of biological medicine, in particular to application of SERPING1-based PASC related cardiovascular system symptom risk assessment. The invention provides a risk assessment system taking SERPING1 as a core molecular marker, and the system can provide objective and quantifiable molecular level reference basis for risk assessment of PASC-related cardiovascular system symptoms under the condition that sufficient explanation is difficult to provide by a conventional detection means.
Nº publicación: CN122768250A 18/09/2026
Applicant:
ZHUHAI HENGQIN AONA REGENERATIVE MEDICINE CO LTD
\u73E0\u6D77\u6A2A\u7434\u5965\u7EB3\u518D\u751F\u533B\u5B66\u6709\u9650\u516C\u53F8
Absstract of: CN122768250A
The invention relates to the technical field of biomedical engineering, in particular to a small molecule composition based on quantitative partial reprogramming, application of the small molecule composition in prevention and treatment of myocardial infarction and an evaluation system. The invention provides a small molecule composition for preventing and treating myocardial infarction. The small molecule composition is prepared from sodium valproate, CHIR99021, Repsox, trans-benzene ring propylamine hydrochloride and forskolin. According to the application disclosed by the invention, a'myocardial epigenetic remodeling safe treatment window '(52-72%) applied to myocardial tissue repair is defined for the first time, and a rat myocardial infarction model is utilized to prove that when the epigenetic age reversal amplitude falls into the window, the most obvious exercise tolerance improvement and the highest 90-day cumulative survival rate can be synchronously obtained; and a clear quantification boundary and end point verification basis is provided for safe application of a partial reprogramming technology in cardiac regenerative medicine.